Mylan Launches Innovative Portfolio of Antiretroviral Products for Treatment of HIV/AIDS in South Africa

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130223:nPnNE64429

Builds on Existing South African Commercial Business
JOHANNESBURG and PITTSBURGH, Feb. 23, 2013 /PRNewswire/ -- Mylan Inc.
(Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical
companies, today announced that its subsidiary in South Africa, Mylan
(Proprietary) Limited, has launched a comprehensive portfolio of antiretroviral
(ARV) products. South Africa has the world's largest HIV/AIDS population, with
approximately 5.6 million1 people living with the disease and an estimated 1.7
million2 people receiving treatment.

Mylan's South African ARV portfolio initially will consist of 11 first- and
second-line adult and pediatric regimens. Included are several innovative
products, such as fixed-dose combinations, single blister "co-packs,"
heat-stable products and novel pediatric formulations that have been approved by
the U.S. Food and Drug Administration (FDA) and the World Health Organization
(WHO).

Mylan CEO Heather Bresch commented, "Mylan's mission is to provide the world's
7 billion people with access to high quality medicine. Recently, Mylan was
awarded a 19% share of the ARV tender conducted by the South African government
and we already have begun to deliver on this commitment. Building on this, today
we are pleased to launch a broad and innovative ARV portfolio for the private
sector. We believe that Mylan can set a new standard in the treatment of
HIV/AIDS in South Africa by providing health care providers and those living
with the disease access to high quality, affordable medicines."

Paul Miller, managing director and vice president of Mylan's South African
business noted, "Mylan is an established leader in ARVs, with a global portfolio
of 43 high quality ARVs, and the company has played a significant role in
reducing the cost of these important therapies. The launch of Mylan's ARV
portfolio in South Africa builds on our existing commercial presence in the
country and is consistent with the company's commitment to addressing unmet
needs with quality products. Mylan's ARV medicines are produced according to
current Good Manufacturing Practices at facilities that have been inspected by
leading regulatory authorities, including the South African Medicines Control
Council, FDA and WHO. These quality standards are paramount everywhere that
Mylan operates, including in South Africa."

Mylan has been a leading global player in the ARV arena for more than a decade.
In 2002, Mylan Laboratories Limited (formerly Matrix Laboratories Limited) began
providing reliable supplies of ARV active pharmaceutical ingredients to generic
drug makers. In 2007, the company began offering finished dosage forms and
launched a line of pediatric ARVs. Today, Mylan is widely respected for the
quality, dependability and affordability of its ARVs. Mylan supplies ARVs to
more than 120 countries around the world and nearly 40% of HIV/AIDS patients
receiving treatment in developing countries depend on one of the company's ARV
products.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit, do what's right, not what's easy and
impact the future through passionate global leadership. We offer a growing
portfolio of more than 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which more than one-third of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 150 countries and
territories. Our workforce of more than 18,000 people is dedicated to improving
the customer experience and increasing pharmaceutical access to consumers around
the world. But don't take our word for it. See for yourself. See inside.
mylan.com

[1] http://www.unaids.org/en/regionscountries/countries/southafrica/

[2] http://www.unaids.org/en/regionscountries/countries/southafrica/

SOURCE Mylan Inc.

Media, Nina Devlin, +1-724-514-1968, or Investors, Kris King, +1-724-514-1813